T. Rowe Price Associates
CTNM

T. Rowe Price Associates’s Contineum Therapeutics CTNM Stock Holding History

T. Rowe Price Associates’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Hold
11,300
– – ﹤0.01% 2918
2025
Q4 		$130K Buy
+11,300
New +$129K ﹤0.01% 2911

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's CTNM Position: Q1 2026 in Review

T. Rowe Price Associates held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 11,300 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #2918.

T. Rowe Price Associates first reported a position in CTNM in Q4 2025 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • T. Rowe Price Associates held 11,300 shares of Contineum Therapeutics worth $148K as of Q1 2026.
  • T. Rowe Price Associates left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2918 holding.
  • T. Rowe Price Associates first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.